- Home
- SLSR vs XNCR Comparison
SLSR vs XNCR Comparison
Compare SLSR & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLSR
- XNCR
- Stock Information
- Founded
- SLSR 2018
- XNCR 1997
- Country
- SLSR Switzerland
- XNCR United States
- Employees
- SLSR N/A
- XNCR N/A
- Industry
- SLSR
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- SLSR
- XNCR Health Care
- Exchange
- SLSR NYSE
- XNCR Nasdaq
- Market Cap
- SLSR 539.0M
- XNCR 579.3M
- IPO Year
- SLSR N/A
- XNCR 2013
- Fundamental
- Price
- SLSR $5.17
- XNCR $8.42
- Analyst Decision
- SLSR Buy
- XNCR Buy
- Analyst Count
- SLSR 2
- XNCR 7
- Target Price
- SLSR $11.00
- XNCR $27.50
- AVG Volume (30 Days)
- SLSR 41.0K
- XNCR 763.4K
- Earning Date
- SLSR 08-08-2025
- XNCR 08-04-2025
- Dividend Yield
- SLSR N/A
- XNCR N/A
- EPS Growth
- SLSR N/A
- XNCR N/A
- EPS
- SLSR N/A
- XNCR N/A
- Revenue
- SLSR N/A
- XNCR $127,228,000.00
- Revenue This Year
- SLSR N/A
- XNCR N/A
- Revenue Next Year
- SLSR N/A
- XNCR $28.84
- P/E Ratio
- SLSR N/A
- XNCR N/A
- Revenue Growth
- SLSR N/A
- XNCR N/A
- 52 Week Low
- SLSR $1.90
- XNCR $7.16
- 52 Week High
- SLSR $5.17
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- SLSR 71.17
- XNCR 44.91
- Support Level
- SLSR $4.51
- XNCR $7.65
- Resistance Level
- SLSR $4.72
- XNCR $8.57
- Average True Range (ATR)
- SLSR 0.21
- XNCR 0.50
- MACD
- SLSR 0.03
- XNCR -0.04
- Stochastic Oscillator
- SLSR 100.00
- XNCR 34.35
About SLSR SOLARIS RESOURCES INC
Solaris Resources Inc is advancing a portfolio of copper and gold assets in the Americas, which includes a high-grade resource with expansion and additional discovery potential at the Warintza copper and gold project in Ecuador; discovery potential on the grass-roots Tamarugo project in Chile and Capricho and Paco Orco projects in Peru, and the La Verde joint venture project.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.